Testosterone Replacement Therapy for Patients with Hypogonadism after High Dose-Rate Brachytherapy for High-Risk Prostate Cancer: A Report of Six Cases and Literature Review
We had six cases of patients who were treated with long-term testosterone replacement therapy (TRT) after high dose-rate (HDR) brachytherapy and androgen deprivation therapy for high-risk prostate cancer. All patients were given testosterone enanthate by intramuscular injection every 3 to 4 weeks. B...
Main Authors: | , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Korean Society for Sexual Medicine and Andrology
2020-01-01
|
Series: | The World Journal of Men's Health |
Subjects: |
id |
doaj-a247ed44195747cfa88a3e5bf8c9bc79 |
---|---|
record_format |
Article |
spelling |
doaj-a247ed44195747cfa88a3e5bf8c9bc792020-11-25T02:26:19ZengKorean Society for Sexual Medicine and AndrologyThe World Journal of Men's Health2287-42082287-46902020-01-0138113213610.5534/wjmh.180130Testosterone Replacement Therapy for Patients with Hypogonadism after High Dose-Rate Brachytherapy for High-Risk Prostate Cancer: A Report of Six Cases and Literature ReviewSuguru Kadomoto0Kazuyoshi Shigehara1Hiroaki Iwamoto2Hiroshi Yaegashi3Kouji Izumi4Yoshifumi Kadono5Atsushi Mizokami6Kanazawa University Graduate School of Medical ScienceKanazawa University Graduate School of Medical ScienceKanazawa University Graduate School of Medical ScienceKanazawa University Graduate School of Medical ScienceKanazawa University Graduate School of Medical ScienceKanazawa University Graduate School of Medical ScienceKanazawa University Graduate School of Medical ScienceWe had six cases of patients who were treated with long-term testosterone replacement therapy (TRT) after high dose-rate (HDR) brachytherapy and androgen deprivation therapy for high-risk prostate cancer. All patients were given testosterone enanthate by intramuscular injection every 3 to 4 weeks. Blood biochemistry including prostate specific antigen (PSA) level was evaluated every 3 to 6 months after TRT, and radiological imaging was performed every 12 months. All patients had slight increases in PSA within the normal range and not indicative of biochemical recurrence. A sudden increase in PSA was observed in one patient, but it finally decreased. Aging male symptoms scale and various metabolic factors were improved by TRT in all of cases. Although adverse events included polycythemia in one patient, no patients experienced disease recurrence or progression during TRT. Our results suggest TRT for high risk-patients with HDR brachytherapy for prostate cancer may be beneficial and safe.hypogonadismprostatic neoplasmssafetytestosterone |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Suguru Kadomoto Kazuyoshi Shigehara Hiroaki Iwamoto Hiroshi Yaegashi Kouji Izumi Yoshifumi Kadono Atsushi Mizokami |
spellingShingle |
Suguru Kadomoto Kazuyoshi Shigehara Hiroaki Iwamoto Hiroshi Yaegashi Kouji Izumi Yoshifumi Kadono Atsushi Mizokami Testosterone Replacement Therapy for Patients with Hypogonadism after High Dose-Rate Brachytherapy for High-Risk Prostate Cancer: A Report of Six Cases and Literature Review The World Journal of Men's Health hypogonadism prostatic neoplasms safety testosterone |
author_facet |
Suguru Kadomoto Kazuyoshi Shigehara Hiroaki Iwamoto Hiroshi Yaegashi Kouji Izumi Yoshifumi Kadono Atsushi Mizokami |
author_sort |
Suguru Kadomoto |
title |
Testosterone Replacement Therapy for Patients with Hypogonadism after High Dose-Rate Brachytherapy for High-Risk Prostate Cancer: A Report of Six Cases and Literature Review |
title_short |
Testosterone Replacement Therapy for Patients with Hypogonadism after High Dose-Rate Brachytherapy for High-Risk Prostate Cancer: A Report of Six Cases and Literature Review |
title_full |
Testosterone Replacement Therapy for Patients with Hypogonadism after High Dose-Rate Brachytherapy for High-Risk Prostate Cancer: A Report of Six Cases and Literature Review |
title_fullStr |
Testosterone Replacement Therapy for Patients with Hypogonadism after High Dose-Rate Brachytherapy for High-Risk Prostate Cancer: A Report of Six Cases and Literature Review |
title_full_unstemmed |
Testosterone Replacement Therapy for Patients with Hypogonadism after High Dose-Rate Brachytherapy for High-Risk Prostate Cancer: A Report of Six Cases and Literature Review |
title_sort |
testosterone replacement therapy for patients with hypogonadism after high dose-rate brachytherapy for high-risk prostate cancer: a report of six cases and literature review |
publisher |
Korean Society for Sexual Medicine and Andrology |
series |
The World Journal of Men's Health |
issn |
2287-4208 2287-4690 |
publishDate |
2020-01-01 |
description |
We had six cases of patients who were treated with long-term testosterone replacement therapy (TRT) after high dose-rate (HDR) brachytherapy and androgen deprivation therapy for high-risk prostate cancer. All patients were given testosterone enanthate by intramuscular injection every 3 to 4 weeks. Blood biochemistry including prostate specific antigen (PSA) level was evaluated every 3 to 6 months after TRT, and radiological imaging was performed every 12 months. All patients had slight increases in PSA within the normal range and not indicative of biochemical recurrence. A sudden increase in PSA was observed in one patient, but it finally decreased. Aging male symptoms scale and various metabolic factors were improved by TRT in all of cases. Although adverse events included polycythemia in one patient, no patients experienced disease recurrence or progression during TRT. Our results suggest TRT for high risk-patients with HDR brachytherapy for prostate cancer may be beneficial and safe. |
topic |
hypogonadism prostatic neoplasms safety testosterone |
work_keys_str_mv |
AT sugurukadomoto testosteronereplacementtherapyforpatientswithhypogonadismafterhighdoseratebrachytherapyforhighriskprostatecancerareportofsixcasesandliteraturereview AT kazuyoshishigehara testosteronereplacementtherapyforpatientswithhypogonadismafterhighdoseratebrachytherapyforhighriskprostatecancerareportofsixcasesandliteraturereview AT hiroakiiwamoto testosteronereplacementtherapyforpatientswithhypogonadismafterhighdoseratebrachytherapyforhighriskprostatecancerareportofsixcasesandliteraturereview AT hiroshiyaegashi testosteronereplacementtherapyforpatientswithhypogonadismafterhighdoseratebrachytherapyforhighriskprostatecancerareportofsixcasesandliteraturereview AT koujiizumi testosteronereplacementtherapyforpatientswithhypogonadismafterhighdoseratebrachytherapyforhighriskprostatecancerareportofsixcasesandliteraturereview AT yoshifumikadono testosteronereplacementtherapyforpatientswithhypogonadismafterhighdoseratebrachytherapyforhighriskprostatecancerareportofsixcasesandliteraturereview AT atsushimizokami testosteronereplacementtherapyforpatientswithhypogonadismafterhighdoseratebrachytherapyforhighriskprostatecancerareportofsixcasesandliteraturereview |
_version_ |
1724847933417848832 |